Dare Bioscience Inc Stock Price, News & Analysis

Daré Bioscience announced the adjournment of its 2025 annual meeting of stockholders due to lack of required quorum, with fewer than a majority of shares present either in person or by proxy. The Annual Meeting will reconvene virtually on July 9, 2025, at 9:00 a.m. Pacific Time. Stockholders of record as of April 17, 2025, who haven't voted can do so online at www.proxyvote.com or by telephone at 1-800-690-6903 until July 8, 2025. Previously submitted proxies and votes remain valid unless properly revoked. The company's definitive proxy statement is available on www.proxyvote.com, the company's investor relations website, and the SEC website.

Daré Bioscience (NASDAQ: DARE) has announced a strategic partnership with Rosy Wellness to support the marketing and awareness campaign for DARE to PLAY Sildenafil Cream, a topical formulation of sildenafil citrate (Viagra's active ingredient) for female sexual arousal. The product is expected to be available by prescription in Q4 2025 as a compounded drug. Rosy Wellness, with its 250,000+ women community and endorsement from 8,000+ healthcare professionals, will leverage its digital platform to provide educational outreach and healthcare provider engagement. The collaboration aims to destigmatize female sexual health discussions, with data showing 65% of women in Rosy's community reporting arousal concerns. Daré expects to begin recording revenue in Q4 2025 through this partnership that combines Daré's clinical expertise with Rosy's digital reach and engagement model.

Daré Bioscience (NASDAQ: DARE) reported its Q1 2025 financial results and provided updates on its women's health product pipeline. The company plans to commercialize four products between 2025-2026, including Sildenafil Cream for female sexual arousal disorder, DARE-HRT1 for menopause symptoms, vaginal probiotics, and Ovaprene for contraception. Financial results show cash and equivalents of $10.3M with a working capital deficit of $9.4M. Q1 expenses decreased with R&D at $2.3M (down 31% YoY) and G&A at $2.3M. The company is pursuing a dual-path strategy, commercializing via 503B compounding while seeking FDA approvals, and plans to launch some products as branded consumer health items. A key milestone includes a data safety monitoring board interim assessment for Ovaprene's Phase 3 trial in July 2025.

Daré Bioscience (NASDAQ: DARE), a biopharmaceutical company focused on women's health, has scheduled its Q1 2025 financial results and company update conference call for May 13, 2025, at 4:30 p.m. Eastern Time. Investors can access the call via phone at (646) 307-1963 (U.S.) or (800) 715-9871 (toll-free) using conference ID 3461324. A live webcast will be available on the company's investor relations website, with replay access until May 27, 2025.

Daré Bioscience (NASDAQ: DARE) announced that CEO Sabrina Martucci Johnson will deliver a keynote address at the Fierce Pharma Engage summit on April 29, 2025. The presentation, titled 'Breaking Barriers, Building Access: Communicating Bold Moves in Women's Health Innovation,' will focus on the company's expanded business strategy incorporating 503B compounding.

The company recently unveiled a dual-path approach for its proprietary Sildenafil Cream formulation, targeting prescription availability in Q4 2025. Daré's portfolio includes XACIATO™, an FDA-approved bacterial vaginosis treatment licensed to Organon, and several first-in-category candidates:

• Ovaprene® - hormone-free monthly contraceptive (licensed to Bayer)
• Sildenafil Cream, 3.6% - for female sexual arousal disorder
• DARE-HRT1 - bio-identical hormone therapy ring

Daré Bioscience (NASDAQ: DARE) has announced its expanded business strategy featuring a dual-path approach for its proprietary Sildenafil Cream formulation, with plans to make it available via prescription in Q4 2025. The company's President and CEO, Sabrina Martucci Johnson, will present these developments at the Jones Healthcare and Technology Innovation Conference on April 9th, 2025.

The strategy includes utilizing Section 503B compounding to expedite market access for select Daré proprietary formulations. The company is also exploring bringing consumer health products to market without prescription requirements. Additional strategic partnerships and timing updates are expected this quarter.

The presentation will be accessible via webcast at 1:00 p.m. PT, with a replay available until April 23, 2025, through the company's investor relations website.

Daré Bioscience (NASDAQ: DARE) reported its full year 2024 financial results and announced plans to make its proprietary Sildenafil Cream available via prescription through 503B compounding in Q4 2025, expecting to generate revenue and cash flow. The company ended 2024 with $15.7 million in cash and a working capital deficit of $3.2 million.

Financial highlights show reduced expenses, with G&A costs down 24% to $9.2 million and R&D expenses decreased 34% to $14.2 million compared to the previous year. Key pipeline developments include the ongoing Ovaprene® Phase 3 contraceptive study, with approximately 125 women expected to complete six months of use by Q2 2025, supported by a $10.7 million non-dilutive grant.

The company is pursuing a dual-path approach for select proprietary formulations, including both FDA approval and 503B framework distribution. Daré plans to invest less than $1 million to support the Sildenafil Cream 503B initiative and expects to provide strategic partnership updates in Q2 2025.

Daré Bioscience (NASDAQ: DARE), a women's health innovation company, has scheduled its full year 2024 financial results conference call and webcast for March 31, 2025, at 4:30 p.m. Eastern Time. The presentation will include both financial performance review and company updates.

Participants can join via phone at (646) 307-1963 (U.S.) or (800) 715-9871 (toll-free) using conference ID 9767621. A live webcast will be available through the Investors section of Daré's website. The webcast recording will remain accessible for replay until April 14, 2025.

Daré Bioscience (NASDAQ: DARE) and Theramex have entered into a co-development and licensing agreement for Casea S, a potential first-in-category biodegradable contraceptive implant. The product is designed to release contraceptive medication over 18-24 months before dissolving, eliminating the need for surgical removal.

A fully-funded Phase 1 trial is currently ongoing, conducted by FHI 360, investigating pharmacokinetics, removability, safety, and tolerability. Daré has received a royalty-free, exclusive license to the US patents for Casea S. There are currently no development costs for either company due to foundation grant funding.

If Phase 1 results are positive, Daré will be responsible for conducting the Phase II study in the US. Future Phase II and III study funding will be shared between both companies, with terms to be determined based on market opportunity in their respective regions.